This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Newborn screening | |
|---|---|
| Name | Newborn screening |
| Caption | Heel prick blood sampling for metabolic screening |
| Specialty | Pediatrics, Medical genetics, Neonatology |
| Symptoms | Asymptomatic at time of screening |
| Complications | Delayed diagnosis, false positives, treatment side effects |
| Onset | Neonatal |
| Frequency | Varies by country and program |
Newborn screening is a public health program that tests neonates shortly after birth for a panel of congenital disorders to enable early intervention. Originating in the mid-20th century, the practice integrates Pediatrics, Medical genetics, Neonatology, and public health systems such as World Health Organization, Centers for Disease Control and Prevention, and national health services. Programs vary widely among countries, influenced by laws, advisory committees, and advocacy from organizations like March of Dimes and Save the Children.
The modern era began after the discovery of phenylketonuria by Asbjørn Følling and the demonstration that dietary management could prevent intellectual disability, prompting programs in the United States and United Kingdom. Pilot screening initiatives in the 1960s involved collaborations among institutions such as Massachusetts General Hospital, Johns Hopkins Hospital, and public bodies like the National Institutes of Health. Technological advances such as the Guthrie test, developed by Robert Guthrie, and later mass spectrometry from teams at Baylor College of Medicine and Brigham and Women's Hospital expanded disorder panels. International diffusion was shaped by guidelines from World Health Organization and regional adoption in countries including Canada, Australia, Germany, Japan, Brazil, and Sweden.
Techniques evolved from bacterial inhibition assays to enzyme assays and tandem mass spectrometry developed by researchers at Vanderbilt University and Harvard Medical School. Common modalities now include dried blood spot analysis, pulse oximetry as used in neonatal units like Great Ormond Street Hospital, DNA-based assays relying on sequencers from Illumina and Thermo Fisher Scientific, and point-of-care devices tested in trials at University College London Hospitals. Laboratory accreditation and quality control are supported by organizations such as Clinical and Laboratory Standards Institute and College of American Pathologists. Newer platforms employ next-generation sequencing protocols pioneered at Broad Institute and Sanger Institute for conditions such as severe combined immunodeficiency first identified via T-cell receptor excision circles in studies at St. Jude Children's Research Hospital.
Program panels range from single-condition screens like phenylketonuria in early United Kingdom programs to expanded panels including medium-chain acyl-CoA dehydrogenase deficiency, cystic fibrosis, congenital hypothyroidism, sickle cell disease, galactosemia, and hearing loss. Specialist centers such as Johns Hopkins University and Children's Hospital of Philadelphia have published outcome data on conditions including severe combined immunodeficiency, spinal muscular atrophy, and homocystinuria. Selection criteria are influenced by frameworks from the Wilson and Jungner principles and advisory committees in jurisdictions like the Advisory Committee on Heritable Disorders in Newborns and Children in the United States.
Implementation is driven by policy instruments including national newborn screening acts, state statutes in the United States, and health service directives in England under National Health Service. Funding and program governance often involve ministries such as the Ministry of Health (Brazil), provincial health authorities in Ontario, and agencies like the European Centre for Disease Prevention and Control. Program expansion debates have involved stakeholders including advocacy groups like Muscular Dystrophy Association, professional societies such as the American Academy of Pediatrics, and ethics bodies including the Nuffield Council on Bioethics.
Positive screens trigger confirmatory diagnostics at referral centers—examples include metabolic clinics at Great Ormond Street Hospital, immunology units at Royal Children's Hospital, and genetics services at Mayo Clinic. Interventions can include dietary therapy pioneered in clinical trials at Boston Children's Hospital, enzyme replacement therapies developed by pharmaceutical firms like Genzyme, gene therapies emerging from trials at University College London and St. Jude Children's Research Hospital, and surgical or medical management in tertiary centers such as Karolinska University Hospital. Care coordination frequently involves multidisciplinary teams linked to patient registries maintained by organizations like International Society for Neonatal Screening.
Programs raise ethical questions about consent practices debated in courts like the Supreme Court of the United States and advisory reports from bodies such as National Bioethics Advisory Commission. Concerns include data privacy standards governed by laws like the Health Insurance Portability and Accountability Act of 1996 in the United States, storage and secondary use of residual dried blood spots contested in litigation involving state departments of health, and equity in access highlighted by civil society organizations including Human Rights Watch. Policy tensions occur between proponents represented by researchers at Harvard Medical School and advocates for strict opt-in models backed by groups active in European Union debates.
Numerous longitudinal studies from institutions like University of California, San Francisco, University of Toronto, and Karolinska Institutet demonstrate reduced morbidity and mortality for screened conditions, with cost-effectiveness analyses published by agencies including Agency for Healthcare Research and Quality and Organisation for Economic Co-operation and Development. Surveillance networks such as the European Surveillance of Congenital Anomalies and registries coordinated by Centers for Disease Control and Prevention monitor population-level impacts. Ongoing research collaborations among Wellcome Trust, Bill & Melinda Gates Foundation, and academic centers aim to refine panels, improve equity, and evaluate long-term psychosocial outcomes.
Category:Public health Category:Pediatrics Category:Medical genetics